Europe's Off-Patent Industry Seeks Action On Shortages
Medicines For Europe Asks New European Commission For ‘Policy Response’
Medicines For Europe has called on EU leaders to take action on the issue of medicine shortages, urging the new European Commission to prioritize prevention measures in its first 100 days.
You may also be interested in...
Christoph Stoller, Teva’s general manager for Germany and Austria, has just been announced as president of European off-patent industry association Medicines for Europe with a two-year mandate. In an exclusive interview, he sets out the organization’s immediate priorities.
Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.